Innovative Dual-Targeting Nanobody Therapy Against ALB and CD4 for HIV Infection

VHH-P806 is a novel, fully humanized nanobody program under active Biological Testing development, designed for the potential treatment of HIV infection. This candidate features a trimeric antibody fusion construct comprised of an alpaca-derived, single-domain antibody targeting albumin (ALB) and nanobodies targeting CD4 molecule (CD4), key to HIV pathogenesis. The targeting strategy leverages precise recognition of both albumin (ALB) and CD4 molecule (CD4), aiming to enhance in vivo half-life and improve targeting of HIV-affected immune cells. VHH-P806 exemplifies a next-generation antibody approach with the promise to address challenges in both viral neutralization and targeted delivery in HIV therapeutics.

Licensing Opportunity

VHH-P806 is open for out-licensing and collaborative partnership opportunities. Interested parties are invited to explore strategic collaborations to accelerate development and facilitate commercialization of this innovative nanobody platform.

Development Phase

Modality

VHH-P806 features a trimeric antibody fusion modality, consisting of single-domain nanobodies with a compact molecular structure, renowned for their stability and remarkable tissue penetration. The construct incorporates an alpaca-derived nanobody against human serum albumin, flanked on both sides by nanobodies targeting CD4, connected by (G4S)3 linkers. Expressed in human embryonic kidney cells, VHH-P806’s modular architecture enables high solubility and robust biophysical properties, offering significant advantages for reaching HIV reservoirs. The reduced molecular size facilitates better tissue distribution and possible mucosal or cellular access compared to conventional antibodies, making VHH-P806 particularly suitable for targeting HIV-infected cells.

Target

ALB and CD4 are the two primary molecular targets of VHH-P806. ALB is a major plasma protein responsible for maintaining oncotic pressure and transporting essential substances in the bloodstream. CD4 is a surface glycoprotein mainly expressed on T-helper lymphocytes, monocytes, and dendritic cells, serving as the primary receptor exploited by HIV for cell entry. ALB’s abundance allows for strategic half-life extension of therapeutics, while targeting CD4 enables focused intervention at the central immune cells involved in HIV infection. Targeting ALB helps prolong circulation time, and engaging CD4 allows for selective delivery of antiviral effects. The dual-targeting strategy of VHH-P806 towards ALB and CD4 highlights a sophisticated approach to maximize both efficacy and pharmacokinetics, underscoring its strategic value for HIV therapy advancement.

Mechanism of Action

VHH-P806 exerts its action through bi-specific engagement, simultaneously binding to ALB and CD4. The anti-ALB component anchors the molecule in the circulatory system, enabling prolonged systemic exposure and optimized pharmacokinetics. The anti-CD4 nanobody provides high-affinity recognition of CD4-positive immune cells, specifically targeting and potentially neutralizing HIV’s primary cell entry receptor. By bridging ALB and CD4, VHH-P806 can provide both extended half-life and precise immunological targeting. The nanobody platform also offers opportunities for derivative therapeutic formats, including antibody-drug conjugates or bispecific constructs, supporting the development of multipronged interventions against HIV and other related infectious diseases.

HIV Infection

HIV infection remains a major global health challenge, with millions living with the virus and substantial new infections each year. HIV attacks CD4-positive immune cells, leading to immune suppression and progressing, if untreated, to AIDS. Treatments currently rely on antiretroviral therapy to suppress viral replication, prevent disease progression, and reduce transmission risk. However, these regimens require lifelong adherence, present challenges of resistance, toxicity, and incomplete immune reconstitution, and do not eliminate latent reservoirs. There remains a significant unmet need for therapies offering new mechanisms, improved delivery, and long-term efficacy. VHH-P806, by targeting both ALB and CD4, introduces a promising therapeutic modality combining optimized pharmacokinetics with targeted immune cell engagement, holding the potential to overcome key barriers in current HIV therapy and advance next-generation treatments.